Cargando…
In Silico Methods for Development of Generic Drug–Device Combination Orally Inhaled Drug Products
The development of generic, single‐entity, drug–device combination products for orally inhaled drug products is challenging in part because of the complex nature of device design characteristics and the difficulties associated with establishing bioequivalence for a locally acting drug product delive...
Autores principales: | Walenga, Ross L., Babiskin, Andrew H., Zhao, Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618094/ https://www.ncbi.nlm.nih.gov/pubmed/31044532 http://dx.doi.org/10.1002/psp4.12413 |
Ejemplares similares
-
Mechanistic modeling of generic orally inhaled drug products: A workshop summary report
por: Walenga, Ross L., et al.
Publicado: (2022) -
Mechanistic modeling of ophthalmic, nasal, injectable, and implant generic drug products: A workshop summary report
por: Tan, Ming‐Liang, et al.
Publicado: (2023) -
Physiologically‐based pharmacokinetic modeling to support bioequivalence and approval of generic products: A case for diclofenac sodium topical gel, 1%
por: Tsakalozou, Eleftheria, et al.
Publicado: (2021) -
Generic-reference and generic-generic bioequivalence of forty-two, randomly-selected, on-market generic products of fourteen immediate-release oral drugs
por: Hammami, Muhammad M., et al.
Publicado: (2017) -
In vitro - in vivo - in silico approach in the development of inhaled drug products: Nanocrystal-based formulations with budesonide as a model drug
por: Shi, Changzhi, et al.
Publicado: (2021)